EBITDA Margin % is calculated as EBITDA divided by its Revenue. TaiMed Biologics's EBITDA for the
three
months ended in Dec. 2025 was NT$-27.5 Mil. TaiMed Biologics's Revenue for the
three
months ended in Dec. 2025 was NT$149.9 Mil. Therefore, TaiMed Biologics's EBITDA margin for the quarter that ended in Dec. 2025 was -18.33%.
TaiMed Biologics (ROCO:4147) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TaiMed Biologics EBITDA Margin % Related Terms
TaiMed Biologics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, TaiMed Biologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a EBITDA Margin % of -18.33% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #309 out of 937 companies in the Biotechnology industry, placing it in the top 33%.
Is TaiMed Biologics' EBITDA Margin % too high?
TaiMed Biologics' current EBITDA Margin % is -18.33%. Based on the distribution chart, TaiMed Biologics ranks #309 out of 937 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #309 out of 937 companies for EBITDA Margin %. This puts TaiMed Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current EBITDA Margin % is -18.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current EBITDA Margin % is -18.33%. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current EBITDA Margin % is -18.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
EBITDA Margin %: -18.33%
GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score
Get the complete analysis for ROCO:4147
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
